Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telmisartan + amlodipine
- Development stage
- Phase 1
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Telmisartan + amlodipine** is an oral fixed-dose antihypertensive combination containing telmisartan, an angiotensin II receptor blocker, and amlodipine, a dihydropyridine calcium-channel blocker. It is used to treat hypertension, including as initial therapy for patients likely to require more than one antihypertensive medicine and as replacement or add-on therapy when blood pressure is inadequately controlled with either component alone. Telmisartan reduces angiotensin II-mediated vasoconstriction and aldosterone signaling through angiotensin II receptor type 1 blockade, while amlodipine relaxes vascular smooth muscle by inhibiting L-type calcium-channel-mediated calcium influx. The originator fixed-dose product is marketed by Boehringer Ingelheim as Twynsta.
- Brand names
- MicamloMicardis AmloMicardis DuoOntelPritor/AmlodipineTwynsta
- Other names
- amlodipine + telmisartanamlodipine/telmisartantelmisartan + amlodipinetelmisartan + amlodipine besilatetelmisartan and amlodipinetelmisartan/amlodipine
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on telmisartan + amlodipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telmisartan + amlodipine.